RemeGen Inks $4.23B Global Licensing Deal for Telitacicept with Vor Biopharma, Files IPO Prospectus

On June 26, RemeGen announced that it would grant a paid license for its proprietary drug, telitacicept, to Vor Biopharma Inc. (“Vor Bio”), a company listed on the NASDAQ in the United States. Under the agreement, Vor Bio will obtain exclusive rights to develop, manufacture, and commercialize telitacicept worldwide, excluding the Greater China region.

As part of the transaction consideration, RemeGen and its wholly-owned subsidiary, Yantai Rongpu Equity Investment Partnership (Limited Partnership) (“Rongpu Partnership”), will receive from Vor Bio cash and warrants valued at $125 million, as well as clinical, regulatory, and commercialization milestone payments of up to $4.105 billion, for a total aggregate value of $4.23 billion (approximately RMB 30.4 billion). In addition, RemeGen will be entitled to high-single-digit to double-digit sales royalties.

Telitacicept is a novel fusion protein product independently developed by RemeGen, representing the world’s first injectable recombinant dual-target agent against B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). Its mechanism of action involves simultaneously inhibiting the binding of these two cytokines, BLyS and APRIL, to their receptors on the surface of B cells, thereby preventing abnormal B-cell differentiation and maturation for the treatment of autoimmune diseases.

Currently, telitacicept has been approved in China for the treatment of three indications: myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. In 2024, the product’s sales in China reached RMB 970 million, representing an 88% year-on-year increase, with sales volume exceeding 1.5 million doses.

A global, multicenter Phase III clinical trial of telitacicept for the treatment of myasthenia gravis is ongoing. This indication has been granted Fast Track designation and Orphan Drug designation by the U.S. FDA, as well as Orphan Drug designation by the European Union.

The $125 million in cash and warrants in this transaction includes a $45 million upfront payment and warrants valued at $80 million. If fully exercised, the warrants would allow holders to subscribe for 320 million ordinary shares of Vor Bio, representing approximately 23% of Vor Bio’s enlarged total issued share capital.

On the day of the announcement, Vor Bio also announced the completion of a private equity financing round involving prominent funds such as RA Capital and Forbion, raising $175 million. Concurrently, Vor Bio announced the appointment of Dr. Jean-Paul Kress as its new Chief Executive Officer and Chairman of the Board. Dr. Kress previously served as CEO of MorphoSys, where he led the development, regulatory approval, and commercialization of Monjuvi (tafasitamab) and strengthened the company’s pipeline through the acquisition of Constellation Pharmaceuticals, ultimately facilitating Novartis’s acquisition of MorphoSys. He also served as CEO of Syntimmune until its acquisition by Alexion Pharmaceuticals. Dr. Kress currently serves as a member of the Board of Directors of Sanofi.

RemeGen stated in its announcement that this transaction will accelerate the global development and commercialization of telitacicept, maximize its product value, and provide significant cash flow support to the company. Meanwhile, the company can concentrate its resources to further consolidate and expand its market in Greater China, and expedite the development of its other innovative product pipelines.

Following the disclosure of the transaction details, the $45 million upfront payment has sparked widespread discussion within the industry.

On June 11, RemeGen stated that at the 62nd Annual Congress of the European Renal Association (ERA), multiple business development managers from multinational pharmaceutical companies proactively approached the company regarding international collaboration and technology licensing for telitacicept. Consequently, the share prices of RemeGen’s A-shares and H-shares surged.

Given Telitacicept’s clinical performance and market attention, many industry participants hold high expectations for the drug, believing it has the potential to become a major business development (BD) deal. Consequently, following the announcement, RemeGen’s shares fell in both the A-share and H-share markets at the opening, driven by an upfront payment that fell short of expectations and a pullback after a previous surge in stock price. As of today’s close, RemeGen’s A-shares dropped 18.36%, while its H-shares declined 11.71%.

However, an in-depth analysis of the transaction structure reveals that RemeGen opted for a non-traditional licensing path with multinational corporations (MNCs), instead partnering with the capital-driven Vor Bio and adopting a “licensing + high-equity-stake” model, which differs significantly from the traditional MNC licensing model.

Specifically, the traditional MNC licensing model can provide higher upfront payments and leverage its robust global network to advance product development; however, it often encounters various challenges during actual implementation.

The advantages of multinational corporations (MNCs) lie in their substantial financial resources, extensive distribution channels, and rich experience. However, they often face challenges such as cumbersome internal systems, lengthy decision-making chains, and a large number of concurrently developed pipelines. These issues may lead to delays in clinical progress and dilute resource allocation for individual projects. Industry statistics show that MNCs take an average of 9–12 months from signing licensing agreements to initiating overseas clinical trials, with some complex projects exceeding 18 months.

In contrast, Vor Bio has positioned telitacicept as its core asset. Leveraging the capital operations expertise and project management capabilities of its lead investor, RA Capital, Vor is poised to dedicate maximum efficiency and resources to accelerate the overseas clinical development of telitacicept, thereby enhancing its commercial value in international markets.

Secondly, in contrast to the dominant bargaining power of multinational corporations (MNCs), licensors are often in a passive position. In terms of revenue structure, MNCs typically capture the majority of profits across a product’s entire lifecycle by leveraging their channel advantages, while licensors primarily rely on a linear model of “upfront payment + milestones + royalties.” However, through this transaction, RemeGen is expected to acquire approximately 23% equity stake in Vor Bio. This implies that, despite the relatively low upfront payment, RemeGen will not only receive future sales royalties but also deeply share in the dividends generated by the growth in Vor Bio’s market capitalization.

Certainly, the success of this model hinges on a key premise: Vor Bio’s core value and stock price are highly dependent on the success of telitacicept, as is the value of RemeGen’s substantial equity stake. Meanwhile, compared with experienced multinational corporations (MNCs), Vor Bio still needs to build its capabilities in global market access and commercialization. Therefore, the future clinical performance and commercial progress of telitacicept will play a decisive role.

Overall, although RemeGen’s latest transaction has sparked some controversy, it represents a worthwhile attempt to seize the initiative in taking innovative drugs global. Whether RemeGen can successfully navigate this new model and realize its anticipated substantial value remains to be seen, pending further developments over time.

References:

RemeGen's Latest BD Deal: Many People Didn't Understand It — Pharmaceutical Investment Tribe